Catalyst Pharmaceuticals, Inc.: Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q19 net revenues of $30.9M and FY19 guidance of approx $100M. Key Firdapse trial readouts in 1H20: Phase 3 trial for MuSK-MG and SMA Type 3 proof of concept trial.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III, Registration Stage
Disease Space
Central Nervous System, Rare Disease
Finance
Pre-Revenues
Industry
Specialty Pharmaceutical
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.